WHAT IS CLAIMED IS:

1. A monoclonal antibody that binds to Notch2 NRR and inhibits Notch2 activity, wherein the antibody binds to both human and mouse Notch2 NRR with a Kd of $\leq$ 10 nM.
2. The antibody of claim 1, wherein the antibody does not bind to Notch1, 3 and 4.
3. The antibody of claim 1, wherein the antibody comprises:
   (a) an HVR-H1 comprising an amino acid sequence that conforms to the consensus sequence of SEQ ID NO:3;
   (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO;4;
   (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:5;
   (d) an HVR-L1 comprising an amino acid sequence that conforms to the consensus sequence of SEQ ID NO:10;
   (e) an HVR-L2 comprising an amino acid sequence that conforms to the consensus sequence of SEQ ID NO: 14; and
   (f) an HVR-L3 comprising an amino acid sequence that conforms to the consensus sequence of SEQ ID NO: 19.

4.The antibody of claim 3, wherein the antibody comprises an HVR-H1 comprising an amino acid sequence selected from SEQ ID NOs: 1-2; an HVR-L1 comprising an amino acid sequence selected from SEQ ID NOs:6-9; an HVR-L2 comprising an amino acid sequence selected from SEQ ID NOs: 11-13; and an HVR-L3 comprising an amino acid sequence selected from SEQ ID NOs:15-18.

5. The antibody of claim 4, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 1, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:6, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:11, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 15.
6. The antibody of claim 4, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO:2, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:7, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:11, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 16.
7. The antibody of claim 4, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO:2, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:8, the

~~HVR-L2 comprises the amino acid sequence of SEQ ID NO:12, and the HVR-L3~~ comprises the amino acid sequence of SEQ ID NO:17.

8. The antibody of claim 4, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO:2, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:9, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:13, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 18.

9. The antibody of claim 3, further comprising at least one framework selected from a human VH Acceptor 2 framework and a human VL kappa subgroup I consensus framework.

10. The antibody of claim 1, wherein the antibody comprises a heavy chain variable domain having at least 90% sequence identity to an amino acid sequence selected from SEQ ID NO:20-21 and a light chain variable domain having at least 90% sequence identity to an amino acid sequence selected from SEQ ID NO:22-25.

11. The antibody of claim 10, wherein the antibody comprises a heavy chain variable domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:20 and a light chain variable domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:22.

12. The antibody of claim 11, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:20, and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:22.

13. The antibody of claim 10, wherein the antibody comprises a heavy chain variable domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:21 and a light chain variable domain having at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs:23-25.

14. The antibody of claim 13, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:21, and the light chain variable domain comprises an amino acid sequence selected from SEQ ID NOs:23-25.

15. The antibody of claim 1, wherein the antibody binds to the same epitope as an antibody selected from Antibody D, Antibody D-1, Antibody D-2, or Antibody D-3.

16. The antibody of claim 15, wherein the antibody binds to the LNR-A domain and the HD-C domain of Notch2.

17. An antibody as in any of the preceding claims, wherein the antibody is an antibody fragment selected from a Fab, Fab'-SH, Fv, scFv, or $(Fab')_2$ fragment.

18. An antibody as in any of the preceding claims, wherein the antibody is human, humanized, or chimeric.

19. A method of inhibiting Notch2 activity *in vitro*, the method comprising exposing a cell that expresses Notch2 to an antibody as in any of claims 1-16.

20. An antibody as in any of claims 1-16 for use in inhibiting Notch2 activity.

21. Use of an antibody as in any of claims 1-16 for the manufacture of a medicament for treating a disorder associated with increased expression or activity of Notch2.

22. Use of an antibody as in any of claims 1-16 for the manufacture of a medicament for treating a B-cell malignancy.

23. Use of an antibody as in any of claims 1-16 for the manufacture of a medicament for treating melanoma.

24. An antibody as in any of claims 1-16 for use as a medicament.

25. An antibody as in any of claims 1-16 for use in the treatment of a disorder associated with increased expression or activity of Notch2.

26. An antibody as in any of claims 1-16 for use in the treatment of a B-cell malignancy.

27. An antibody as in any of claims 1-16 for use in the treatment of melanoma.

WHAT IS CLAIMED IS:

1. A monoclonal antibody that binds to the Lin12/Notch Repeat (LNR)-A domain and the heterodimerization domain (HD)-C domain of the Notch2 negative regulatory region (NRR) and inhibits Notch2 activity, wherein the antibody binds to both human and mouse Notch2 NRR with a Kd of $\leq$ 10 nM and wherein the antibody comprises an HVR-H1 comprising an amino acid sequence selected from SEQ ID NOs:1-2; an HVR-H2 comprising the amino acid sequence of SEQ ID NO:4; an HVR-H3 comprising the amino acid sequence of SEQ ID NO:5; an HVR-L1 comprising an amino acid sequence selected from SEQ ID NOs:6-9; an HVR-L2 comprising an amino acid sequence selected from SEQ ID NOs: 11-13; and an HVR-L3 comprising an amino acid sequence selected from SEQ ID NOs:15-18.

2. The antibody of claim 1, wherein the antibody does not bind to Notch1, 3 and 4.

3. The antibody of claims 1 or 2, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 1, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:6, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:11, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 15.

4. The antibody of claims 1 or 2, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO:2, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:7, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:11, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 16.

5. The antibody of claims 1 or 2, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO:2, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:8, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:12, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 17.

6. The antibody of claims 1 or 2, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO:2, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:9, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:13, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 18.

7. The antibody of any one of claims 1 to 6, further comprising at least one framework selected from a human VH Acceptor 2 framework and a human VL kappa subgroup I consensus framework.

8. The antibody of any one of claims 1 to 7, wherein the antibody comprises a heavy chain variable domain having at least 90% sequence identity to an amino acid sequence selected from SEQ ID NO:20-21 and a light chain variable domain having at least 90% sequence identity to an amino acid sequence selected from SEQ ID NO:22-25.

9. The antibody of any one of claims 1 to 8, wherein the antibody comprises a heavy chain variable domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:20 and a light chain variable domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:22.

10. The antibody of claim 9, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:20, and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:22.

11. The antibody of any one of claims 1 to 7, wherein the antibody comprises a heavy chain variable domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:21 and a light chain variable domain having at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs:23-25.

12. The antibody of claim 11, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:21, and the light chain variable domain comprises an amino acid sequence selected from SEQ ID NOs:23-25.

13. The antibody as in any of the preceding claims, wherein the antibody binds to the same epitope as an antibody comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; an HVR-H2 comprising the amino acid sequence of SEQ ID NO:4; an HVR-H3 comprising the amino acid sequence of SEQ ID NO:5; an HVR-L1 comprising the amino acid sequence of SEQ ID NO:6; an HVR-L2 comprising the amino acid sequence of SEQ ID NO:11; and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:15.

14. An antibody as in any of the preceding claims, wherein the antibody is an antibody fragment selected from a Fab, Fab'-SH, Fv, scFv, or $(Fab')_2$ fragment.